Orpheris is a clinical stage neuroscience company leveraging a novel platform technology from Johns Hopkins that enables the selective delivery of therapeutic agents across the blood barrier into activated microglial cells.
Orpheris is focused on the treatment of neuroinflammatory diseases that result in death or severe disabilities, including childhood cerebral adrenoleukodystrophy (ccALD), Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Rett syndrome and autism spectrum disorders.
Jeffrey L. Cleland, Executive Chair, Co-founder
Stephen L. Huhn, Acting Chief Medical Officer
Matt Brewer, Acting Chief Business Officer
Kannan Rangaramanujam, Chief Technology Officer, Co-founder
Sujatha Kannanl, Co-founder